Singapore-headquartered biotechnology company Kyan Technologies has received licensing approval from the country’s Minstry of Health for its clinical laboratory facility. The approval is pivotal for the company, which aims to bridge the gap in cancer care.

Kyan Technologies will be able to provide the functional precision medicine test, Optim.AITM, which supports oncologists in making clinical decisions when treating cancer patients.

Read more: Biotech startup Kyan Therapeutics closes US$5m oversubscribed pre-Series A round

“Singapore becomes the first country to offer this breakthrough technology to support cancer patients,” says the company’s CEO Hugo Saavedra in a statement. “Our team is already hard at work to expand and bring our unique solution to millions of patients all over the world. The licensing approval of our lab moves us one step further to fulfil our mission.”

Kyan Technologies, which was co-founded by 2019 Gen.T honouree Dean Ho, leverages its technology platforms to identify safe and effective drug-dose combinations based on small data.

The newly licensed laboratory will conduct Laboratory Developed Tests, offering guidance on lymphoma cases. It will also study other cancer indications, including for breast and colorectal cancer. Through collaborations with academic institutions, clinical partners and pharmaceutical companies, the laboratory seeks to drive innovation and facilitate the translation of scientific discoveries into practical clinical applications.

See more news about the Gen.T community.